Acute severe ulcerative colitis represents a critical medical emergency requiring urgent inpatient management and intensive corticosteroid therapy. Consequently, Day 1 prognostic scores offer clinicians an objective method to predict corticosteroid failure right at hospital admission. Historically, medical teams waited for Day 3 Oxford criteria before escalating medical care. However, early risk stratification allows clinicians to anticipate non-response and organize timely rescue interventions. Furthermore, contemporary multicenter validation studies provide vital clarity on these scoring systems across modern hospital cohorts.

Evaluating Day 1 Prognostic Scores in Acute Colitis

Clinicians manage acute severe ulcerative colitis by administering prompt intravenous corticosteroids to suppress intense bowel inflammation. Nevertheless, approximately one-third of hospitalized patients fail standard steroid therapy and require advanced medical rescue or emergent colectomy. The Oxford criteria traditionally guide decision-making on Day 3 of treatment. However, waiting 72 hours can delay crucial rescue therapies in high-risk patients. For this reason, researchers developed Day 1 prognostic scores to forecast therapeutic trajectories immediately upon hospital presentation. The validated tools assess standard parameters, including systemic inflammatory markers, serum albumin concentrations, stool frequency, and endoscopic severity indices. Specifically, the Admission Model for Intensification of Therapy in Acute Severe Colitis, known as ADMIT-ASC, incorporates routine laboratory values alongside baseline clinical features. Similarly, the Albumin-C reactive protein-Endoscopy, or ACE index, combines simple objective variables to calculate treatment failure probability. In addition, the Risk of Rescue model utilizes comprehensive clinical markers to generate a continuous failure estimate. Consequently, these scoring systems offer practical frameworks to augment early clinical judgment in acute gastrointestinal admissions.

Comparing ADMIT-ASC, ACE, and ROR Model Accuracy

The contemporary multicenter investigation evaluated 238 adults admitted with acute severe colitis across three tertiary Australian hospitals. Among this cohort, 134 individuals met established criteria for steroid non-response and required rescue medical therapy. The investigators directly evaluated the discriminative capacity of ADMIT-ASC, ACE, and ROR scores using receiver operating characteristic curves. Notably, all three tools demonstrated moderate discriminative capability in real-world patient management. The Risk of Rescue score achieved the highest area under the receiver operating characteristic curve, reaching 0.72. Meanwhile, the ADMIT-ASC score recorded an area of 0.68, and the ACE index demonstrated an area of 0.66. Statistical testing revealed no significant difference among these receiver operating characteristic values, yielding a p-value of 0.17. Therefore, each model provides comparable overall prognostic capability for predicting steroid failure during initial presentation. Furthermore, these findings confirm that simple objective clinical parameters reliably capture early inflammatory severity. Clinicians can thus apply these models to identify vulnerable patients during their first hospital day.

Balancing Diagnostic Sensitivity and Specificity

Although the three scoring systems share similar overall discrimination, their clinical utility diverges at published cutoff thresholds. Specifically, the ADMIT-ASC score and the ACE index provide high specificity but lower diagnostic sensitivity. This characteristic means that these two scores reliably confirm patients destined to fail steroid therapy when positive. However, their low sensitivity means that they fail to capture many patients who ultimately require rescue medications. Conversely, the Risk of Rescue score yields significantly higher sensitivity while displaying lower diagnostic specificity. Consequently, the ROR model captures a broader proportion of failing patients, although it generates more false-positive warnings. Clinicians must therefore understand these distinct statistical trade-offs when selecting a tool for bedside application. A high-specificity model prevents unnecessary escalation in patients who might improve on steroids alone. On the other hand, a sensitive tool ensures that teams do not miss deteriorating patients needing prompt intervention. Thus, practitioners should match the chosen predictive tool to their specific institutional resources and clinical objectives.

Performance Across Biologic-Naive and Biologic-Exposed Cohorts

Modern inflammatory bowel disease cohorts feature increasing numbers of individuals who have previously used biologic therapies. Historically, prior biologic exposure correlated with reduced response to rescue therapies and altered inflammatory dynamics. Therefore, clinicians questioned whether Day 1 prognostic scores retain accuracy in biologic-exposed patients compared to biologic-naive individuals. Fortunately, subgroup analyses in this contemporary study demonstrated consistent discriminative performance across both clinical populations. The predictive accuracy of the Day 1 scores remained broadly similar regardless of prior advanced therapy exposure. This consistency represents an essential finding for contemporary practice, where multiple therapeutic lines are common. Furthermore, the findings indicate that acute mucosal inflammation drives short-term steroid failure rather than past medication history alone. As a result, clinicians can confidently implement these risk models without adjusting calculations for prior biologic use. Consequently, Day 1 assessment tools maintain robust diagnostic value across diverse, real-world inflammatory bowel disease patient demographics.

Clinical Implications for Multidisciplinary Inpatient Management

Hospitalized patients with acute severe ulcerative colitis require structured multidisciplinary care involving gastroenterologists, colorectal surgeons, and specialized nurses. Early identification of corticosteroid non-response enables teams to accelerate decision-making timelines without waiting passively for Day 3. For instance, high-risk scores can prompt immediate baseline screening for opportunistic infections such as tuberculosis and viral hepatitis. In addition, teams can schedule early colorectal surgical consultations and engage enterostomal therapy specialists for patient counseling. Furthermore, early risk identification allows physicians to prepare second-line medical rescue therapies, including infliximab, cyclosporine, or upadacitinib. Meanwhile, clinicians should recognize that Day 1 scores serve as clinical adjuncts rather than replacements for ongoing bedside assessment. Providers must synthesize score predictions with serial abdominal examinations, vital signs, and evolving stool patterns. By integrating objective prognostic scores into standard clinical workflows, care teams can minimize therapeutic delays and optimize clinical outcomes.

What are the primary Day 1 prognostic scores used in acute ulcerative colitis?

Clinicians primarily utilize three Day 1 prognostic tools to evaluate acute severe ulcerative colitis upon hospital admission. Specifically, these models include the ADMIT-ASC tool, the ACE index, and the Risk of Rescue score. These risk scoring systems incorporate admission laboratory markers, patient vital signs, and early endoscopic evaluation. Consequently, physicians can estimate the likelihood of intravenous steroid failure early. This structured approach helps medical teams prepare timely rescue medical therapies.

How does the Risk of Rescue score compare with ADMIT-ASC and ACE?

The Risk of Rescue score demonstrates higher sensitivity compared to the ADMIT-ASC and ACE scoring models. Therefore, it effectively captures a broader population of patients who might fail first-line intravenous corticosteroid therapy. However, this higher sensitivity comes with lower diagnostic specificity. In contrast, the ADMIT-ASC and ACE scores provide greater specificity. Consequently, clinicians must balance these statistical trade-offs when selecting an appropriate scoring model to guide early clinical management.

Why should clinicians evaluate Day 1 prognostic scores rather than waiting for Day 3?

Traditional management relies on Day 3 Oxford criteria to identify steroid non-responders in the hospital. However, delaying escalation until Day 3 can prolong systemic inflammation and increase surgical morbidity in severe cases. Therefore, evaluating Day 1 prognostic scores allows clinicians to anticipate treatment failure immediately upon hospital admission. This proactive assessment facilitates early surgical consultation, multidisciplinary planning, and prompt initiation of second-line biologic or small-molecule rescue therapies without unnecessary delays.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Subhaharan D et al. Contemporary multicentre validation and comparative performance of Day 1 prognostic scores in acute severe ulcerative colitis. J Crohns Colitis. 2026 Oct 09. doi: undefined. PMID: 42854106.
2. Croft A et al. A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis. Aliment Pharmacol Ther. 2024;60(7):920-930.
3. Corte C et al. The ACE (Albumin, CRP and Endoscopy) index in acute colitis: a simple clinical index on admission that predicts outcome in patients with acute ulcerative colitis. United European Gastroenterol J. 2020;8(7):798-806.